Thrombolytic therapy for acute ischaemic stroke: Successful implementation in an Australian tertiary hospital

Internal Medicine Journal

Volumn 36, Issue 8, 2006, Pages 483-488

  Bray, J E ^a   Coughlan, K ^a   Bladin, C ^a  

^a BOX HILL HOSPITAL   (Australia)

Author keywords

Australia; Cerebrovascular accident; Stroke; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANKIN SCALE; TERTIARY HEALTH CARE; TRANSIENT ISCHEMIC ATTACK;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VICTORIA;

EID: 33745603725     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01127.x     Document Type: Article

References (24)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
2. Ingall TJ, O'Fallon WM, Asplund K Goldfrank LR, Hertzberg VS, Louis TA et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-24.
3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
4. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice. A meta-analysis of safety data. Stroke 2003; 34: 2847-50.
5. Wardlaw JM, del Zoppo GJ, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 3: CD 000213.
6. Bailey PM. Thrombolysis for acute ischaemic stroke: revisiting the evidence. Med J Aust 2003; 179: 388-9.
7. Hoffman JR. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little. Med J Aust 2003; 179: 333-4.
8. Smith BJ. Thrombolysis for acute ischaemic stroke: revisiting the evidence. Med J Aust 2003; 179: 386-7.
9. Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE et al. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178: 324-8.
10. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S et al. Improved reliability of the NIH stroke scale using video training. NINDS TPA stroke study group. Stroke 1994; 25: 2220-26.
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
12. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-11.
13. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 1995; 274: 1017-25.
14. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 1151-8.
15. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-20.
16. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35: e27-29.
17. Hickenbottom SL, Morgenstern LB. Educating North America: lessons learned. J Stroke Cerebrovasc Dis 2002; 11: 174-82.
18. Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 2001; 32: 1074-8.
19. Grotta JC, Burgin WS, El Mitwalli A, Long M, Campbell M, Morgenstern LB et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58: 2009-13.
20. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29: 1544-9.
21. Herlitz J, Ekstrom L. Hartford M, Karlson BW, Karlsson T, Grip L. Characteristics and outcome of patients with ST-elevation infarction in relation to whether they received thrombolysis or underwent acute coronary angiography: are we selecting the right patients for coronary angiography? Clin Cardiol 2003; 26: 78-84.
22. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34: 799-800.
23. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162: 1994-2001.
24. Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) [internet based registry] [cited 2005 May 23]. Available from: URL: http://www.acutestroke.org